Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
47
-
Total 13F shares, excl. options
-
24M
-
Shares change
-
+3.81M
-
Total reported value, excl. options
-
$66.8M
-
Value change
-
+$11.8M
-
Number of buys
-
21
-
Number of sells
-
-26
-
Price
-
$2.78
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q4 2019
62 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q4 2019.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 47 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24M shares
of 193M outstanding shares and own 12.42% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (5.67M shares), Foresite Capital Management IV, LLC (3.71M shares), JENNISON ASSOCIATES LLC (2.94M shares), Point72 Asset Management, L.P. (1.9M shares), MORGAN STANLEY (1.87M shares), LADENBURG THALMANN FINANCIAL SERVICES INC. (1.77M shares), COWEN AND COMPANY, LLC (926K shares), Hudson Bay Capital Management LP (850K shares), BANK OF MONTREAL /CAN/ (717K shares), and VANGUARD GROUP INC (636K shares).
This table shows the top 47 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.